Big News: FounderDating is joining OneVest to build the largest community for entrepreneurs. Details here
Latest Notifications
You have no recent recommendations.

Itshak Golan

Advisor Twickenham, United Kingdom, GB

Expert / Projects Evaluator for Horizon 2020 Program, European Commission and CEO & Director, Daniel & Daisy Novel Therapeutics Ltd..

Expert / Projects Evaluator for Horizon 2020 Program, European Commission and CEO & Director, Daniel & Daisy Novel Therapeutics Ltd..

1 vouches

Involved In


Daniel & Daisy Novel Therapeutics Ltd.
Maimonidex RA Ltd.


Welsh Government
Sourasky Tel-Aviv Medical Center (Ichilov Hospital) / Rheumatology Department
EU Commission
Sourasky Tel-Aviv Medical Center (Ichilov Hospital) / Rheumatology Department


Senior Programme Manager LGC / National Institute for Health Research (NIHR) July 2015 - present
Expert / Projects Evaluator for FP7 / Horizon 2020 Programs European Commission February 2012 - present
Founder & Director Daniel & Daisy Novel Therapeutics Ltd. April 2011 - present
Director Maimonidex UK Ltd. February 2008 - present
CEO & Founder Maimonidex RA Ltd. September 2003 - present
Regional R&D / Innovation Manager College of Medicine, Swansea University July 2010 - December 2012
Honorary Senior Lecturer College of Medicine, Swansea University July 2009 - July 2011
Honorary Principal Research Fellow Kennedy Institute of Rheumatology, Imperial College February 2007 - March 2009
Scientific Advisor Sourasky Tel-Aviv Medical Center (Ichilov Hospital) / Rheumatology Department June 2002 - June 2007
Lecturer The Lautenberg Center for General and Tumor Immunology, The Hebrew University, Hadassah Medical Scho January 1999 - August 2003


Tel-Aviv University, Faculty of Life Sciences Cell Research and Immunology 1992 - 1997
Tel-Aviv University, Faculty of Medicine Human Microbiology 1988 - 1992
Makif Gimel, Ashdod, Israel 1978 - 1982

Interested In

Markets of Interest
  • • Education
  • • Healthcare
  • • Small Businesses
  • • Higher Education
  • • Medical Devices

You Should Know About Me

Key Strengths

Project management • Business Development • Business Management • Business planning • Business Strategy • Entrepreneurship • Portfolio Management • Startup Operations • Startups • Consulting roles in bio-medical research • Scientific • Senior Managerial

Key Accomplishments


Senior Programme Manager July 2015 – November 2015
LGC Ltd./NIHR, Twickenham, UK

Key Achievements
 Management of portfolio of 17 funded programs of medical devices, diagnostic and innovative biotechnology projects with total budget of £22M, including involved in capturing of key outputs and their impact on delivering patient benefit.
 Coordinate and support the funding processes and to ensure effective monitoring of funded projects.
 Due diligence of project proposals and funded projects, including the critical analysis of the project rationale and the proposed intellectual property (IP) and commercialization arrangements as well as relevant regulatory and ethical issues.
 Managing complex stakeholder situations and possess a creative approach to problem solving.
 Line management and supporting team members and the improvement of operational processes and working practices.

Editorial Board Member May 2014 – Present
MedCrave Group, MOJ Immunology, Bartlesville, Oklahoma, USA

Key Achievement
Voluntary Role; contributing, from my experience and knowledge, to the publication process of scientific articles in MOJ Immunology.

Expert / Projects Evaluator / Consultant February 2012 – Present
EU Commission, Brussels, Belgium

Key Achievements
 Delivering high quality evaluation of biotechnology, scientific and training programs funded by EU Commission; the process including evaluation and mark the technology, commercial aspects, legal & IP, WPs and budget as well as regulatory and ethical issues relevant to the submitted proposals.
 Actively leading and chairing the discussions of the final panel / experts meetings in Brussels and approving funds of €3M-€10M for academic and commercial projects; medical devices, diagnostic and therapeutic programs.
 Since Horizon 2020 Program launched, on 2014, I evaluated more than 150 research programs for the EU Commission and was involved directly in approval of more than €300M funds for innovative projects.

Founder & Director
Daniel & Daisy Novel Therapeutics Ltd., Swansea, UK April 2011 - Present
Maimonidex (UK) Ltd., Swansea, UK February 2008 - Present
Maimonidex RA Ltd., Tel-Aviv, Israel September 2003 – June 2008

Key Achievements
 Managing all scientific and business activities of the companies, including;
• Preparation of the annual and long term scientific plans; pre-clinical and clinical.
• Preparation of the business plan, commercialization, dissemination and implementation programs.
 Fund raising via national and international organizations as well as via business collaborations with commercial companies including financial management of the companies’ budgets. Total fund that was raised for the R&D activity of the companies is; £1,888,828 GBP.
 Establishment of productive and very active R&D collaborations with leading national and international organizations (Universities and Companies); more than 20 successful R&D collaborations were performed.
 IP generation; from 2000-2015 six families of patents were submitted covering the core technology of the companies in the field of inflammatory diseases and cancer. The rheumatoid arthritis patents were granted in Europe and USA.
 The estimate commercial value of the technologies / the companies generated is; £5M.

Regional R&D / Innovation Manager July 2010 – December 2012
Honorary Senior Lecturer July 2009 – July 2011
College of Medicine, Swansea University, Swansea, UK

Key Achievements
 Identifying, developing and supporting clinical research and scientific collaboration opportunities for individual (and academic groups), SMEs and other businesses operating and based in the ILS / College of Medicine.
 Creating more than 30 national and international linkages / R&D collaborations with programmes and organisations (national and international) that benefit regional life science companies.
 Providing commercial assistance to SMEs and other companies relating to business development, finance, intellectual property rights, regulation and other aspects of developing life science products and services.
 Support the delivering of the innovation and regional economic development activity through participation in workshops, seminars and other engagements assisting businesses within the life science sector.
 Promoting equality and diversity in working practices and maintaining positive working relationships.
 In the role of Honorary Senior lecturer; successful establishment of my scientific research in the College of Medicine in the fields of cancer and autoimmune inflammatory diseases.

Honorary Principal Research Fellow February 2007 – March 2008
Kennedy Institute of Rheumatology, Imperial College, London, UK

Key Achievements
 Establishment of my scientific research in the Kennedy Institute in the field of autoimmune inflammatory diseases / rheumatoid arthritis.
 MaimoniDex (UK) Ltd. and Kennedy Institute were successfully participated in big European program / consortium for arthritis research; SEVENTH FRAMEWORK PROGRAMME, THEME HEALTH, FP7-HEALTH-2007-B. Project full title: Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes with Innovative Therapy Choices.

Senior Scientific Consultant June 2002 – June 2007
Sourasky Tel-Aviv Medical Center (Ichilov Hospital), Rheumatology Department, Tel-Aviv, Israel

Key Achievements
 Managing and lead all scientific and clinical activities/projects of the rheumatology department.
 Fund raising for the pre-clinical / R&D research for the rheumatology department; $350K was raised.

Lecturer January 2000 – August 2003
The Lautenberg Centre for General and Tumour Immunology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel

Key Achievements
 Head of the commercial project for developing novel monoclonal antibody for therapy and diagnosis of rheumatoid arthritis. Leading the group for arthritis research in the centre.
 Teaching duties; Advanced Techniques in Immunology Course.
 IP generation; 3 family of patents were submitted covering the CD44 technology developed for arthritis research. This technology was licensed from the Hebrew University after establishment of Maimonidex RA Ltd.


D.O.B. 10/10/1964 Languages; Fluent English, Hebrew, Georgian and Basic Russian British Citizen

Post Doctorate Training, The Lautenberg Centre for General and Tumour Immunology, The Hebrew University, Hadassah Medical School, Jerusalem, Israel 1999-2000

Post Doctorate Training, R&D Department, B.T.G. Israel Ltd., Rehovot, Israel 1997-1998

Ph.D. in Cell Research and Immunology, Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel 1992-1997
M.Sc. in Human Microbiology, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 1988-1992
B.Sc. in Biology, Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel 1985-1988

Editorial Board Member
MedCrave Group, MOJ Immunology, Bartlesville, Oklahoma, USA May 2014 – Present


The Kaye Innovation Award of Hebrew University of Jerusalem for: “Novel CD44 Variant, Potential Target in the Therapy of Rheumatoid Arthritis”, June 2002.
European Commission Award to Israel and Israel Directorate for EU FP, to honor the most outstanding 2008 Israeli projects in the EU 7th Framework Program for Research & Technological Development, October 2008.


14 Publication in scientific professional journals.
36 Patents in the field of cancer and autoimmune inflammatory disease (rheumatoid arthritis).
National & International Conferences; actively participating and presenting my research work in both academic and commercial conferences.

How I like to work with people
As an Advisor


Scientific Technical Expertise of Life Sciences / Biotechnology / Pharmaceutical Industry
? Molecular Techniques: Extraction, Identification and Characterization of Cellular DNA and RNA, Molecular Hybridization Experiments, Preparation of Probes, Amplification of Nuclear Acids, Plasmids Preparation, Extraction and Transformation Experiments.
? Cytogenetic Techniques: FISH Experiments, Preparation of Cell Karyotype, Immunohistochemistry Experiments.
? Tissue Culture Techniques: Cell Growth and Cloning, Transfection and Infection Techniques, Flow Cytometry Analysis, Sorting of Cells to Different Sub-Populations, Immunofluorescence Assay.
? In-Vivo Techniques: Determination of Tumorigenicity, Preparation of Cells from Different Tissues, Establishment and Study of Various Animal Models.
? Bio-panning Technology: Working with Peptide/Ab Libraries, Binding Experiments, ELISA.
? Proteins Expression and Purification.
? Monoclonal / Polyclonal Antibody Preparation: Immunization of Animals, Testing of Polyclonal Antibody Presence, Cell Fusion Techniques and Hybridoma Production, Large Volume Preparation and Purification of Antibodies.

Business Development Skills
? Project Management.
? Risk Analysis.
? Commercial and Market Analysis.
? Business Plans Preparation.
? Outstanding Negotiation Skills.
? Management of Contracts, IP and other Legal Activities.

Consulting Expertise & Experience;
Projects Evaluator and Monitoring Expert for Funding Organizations (EU Commission & NIHR)
? Supporting and/or coordinating all aspects of program management, including advising potential applicants, checking outline applications for eligibility, reviewing and short-listing of applications for funding, coordinating and managing the peer review process and providing feedback to successful and unsuccessful applicants.
? Undertaking due diligence of proposals based on critical assessment of new product opportunities (therapeutics, medical devices and diagnostics), including reviewing the scientific, technical and clinical rationale, analysis of project budgets and value for money, evaluation of proposed IP protection and freedom to operate positions as well as regulatory and ethical issues and assessment of the proposed commercialization strategy.
? Negotiating funding agreements for projects recommended for funding, including the negotiation of mile-stones, financial arrangements and reporting requirements to enable successful project development.
? Managing a portfolio of projects at various stages of development and across all healthcare sectors, including monitoring of scientific, technical and clinical progress and of the project finances to ensure appropriate translation strategies are in place leading to commercial/patient benefit realization for the funded projects.
? Acting as a member of project Research Steering Groups and Intellectual Property Management Groups to represent the programs’ perspective and facilitate successful project development towards commercialization.
? Supporting the general development of the funding programs, including funding strategy, scoping of themes for calls, portfolio analysis, review of operational processes, etc.
? Line management of Program Managers (PM) and/or Assistant Program Managers (APM), including supporting PMs in their due diligence, contracting and project management activities.
? Recruitment, training and mentoring of PMs and APMs.
? Organizing and leading meetings with internal and external stakeholders.
? Promoting and representing the programs at external meetings.
? Contributing to the response to Parliamentary Questions or briefing requests from the Department of Health / EU Commission.

Vouches Received

Vouches Given

Think Itshak is awesome?
Vouch for them.

Michael Palfreyman
They're my advisor  •  Chairman of the Board, Amakem Therapeutics, NV and Senior R&D Diligence, Torrey Pines Investment.
Itshak has wide experience of the drug discovery and development process and is well networked into expert professionals to supplement his e ... xtensive skills set.